SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CTI BioPharma Corp. (CTIC) .
本页证实的标准:
- VALUE (60/100, 通过) — 分析师目标价暗示上行空间 (+14.3%).
- 分析师共识目标价 $10.40 (+14.3% 上行空间) — 预期温和上涨。
SharesGrow 综合评分： 31/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
60/100
Price-to-Earnings & upside
Proven by this page
✗
健康
25/100
Debt-to-Equity & liquidity
→ Health
估值概览 — CTIC
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率19.34
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.79
每股账面价值$0.00
每股营收$0.47
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$10.40 (+14.3%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$-3.74 |
$34.68M |
$-42.74M |
-123.3% |
| 2014 |
$-6.29 |
$60.08M |
$-93.37M |
-155.4% |
| 2015 |
$-4.26 |
$16.12M |
$-119.42M |
-741% |
| 2016 |
$-1.86 |
$57.41M |
$-52.01M |
-90.6% |
| 2017 |
$-1.12 |
$25.15M |
$-40.67M |
-161.7% |
| 2018 |
$-0.52 |
$26.29M |
$-29.32M |
-111.5% |
| 2019 |
$-0.73 |
$3.35M |
$-42.32M |
-1265.1% |
| 2020 |
$-0.74 |
$0.00 |
$-52.95M |
- |
| 2021 |
$-1.11 |
$0.00 |
$-99.64M |
- |
| 2022 |
$-0.79 |
$53.95M |
$-91.04M |
-168.8% |
